A Levitzki
- Oncology top 2%
- HER2/EGFR in Cancer Research 8
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments 4
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 3
- Immunology and Allergy top 5%
- Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer 5
- Protein Kinase Regulation and GTPase Signaling 3
- Chemical Synthesis and Analysis 2
-
- Fungal Plant Pathogen Control 4
-
- Monoclonal and Polyclonal Antibodies Research 4
- Co-authors
- Aviv GazitChaim GilonMichal ShaharMelvin H. FreedmanEnrico ArpaiaHarjit DadiJ. Steven LeederChaim M. Roifman
- Cited by
- OncologyHematologyGenetics
- Partner nations
- IsraelUnited StatesFrance
In The Last Decade
A Levitzki
26 papers receiving 3.0k citations
Hit Papers
Peers
Comparison fields: 5 of 108
- Oncology 1.1k
- Hematology 395
- Genetics 324
- Immunology and Allergy 171
- Molecular Biology 1.8k
Countries citing papers authored by A Levitzki
This map shows the geographic impact of A Levitzki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Levitzki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Levitzki more than expected).
Fields of papers citing papers by A Levitzki
This network shows the impact of papers produced by A Levitzki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Levitzki. The network helps show where A Levitzki may publish in the future.
Co-authorship network
The 25 scholars most cited alongside A Levitzki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 69 | |
| 2 | 2004 | 26 | |
| 3 | 2004 | 17 | |
| 4 | Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. | 2001 | 37 |
| 5 | 2001 | 78 | |
| 6 | An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies. | 2001 | 18 |
| 7 | 1999 | 352 | |
| 8 | 1999 | 184 | |
| 9 | 1998 | 42 | |
| 10 | Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. | 1996 | 74 |
| 11 | 1996 | 46 | |
| 12 | Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitorbreakdown → | 1996 | 799 |
| 13 | 1994 | 58 | |
| 14 | 1994 | 21 | |
| 15 | Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. | 1994 | 66 |
| 16 | 1994 | 25 | |
| 17 | 1993 | 8 | |
| 18 | 1992 | 33 | |
| 19 | 1992 | 274 | |
| 20 | 1990 | 8 |
About A Levitzki
A Levitzki is a scholar working on Hematology, Oncology, Toxicology, Genetics and Physiology, having authored 26 papers that have together received 3.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (8 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Fungal Plant Pathogen Control (4 papers), Chronic Myeloid Leukemia Treatments (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Protein Kinase Regulation and GTPase Signaling (3 papers) and Chemical Synthesis and Analysis (2 papers). The work is most often cited by research in Oncology (1.1k citations), Hematology (395 citations), Genetics (324 citations), Immunology and Allergy (171 citations) and Molecular Biology (1.8k citations). A Levitzki has collaborated with scholars based in Israel, United States and France. Frequent co-authors include Aviv Gazit, Chaim Gilon, Michal Shahar, Melvin H. Freedman, Enrico Arpaia, Harjit Dadi, J. Steven Leeder, Chaim M. Roifman, Amos Cohen and Frank Sicheri. Their work appears in journals such as Molecular Pharmacology, The EMBO Journal, Blood, Journal of Pharmacology and Experimental Therapeutics and FEBS Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.